UroGen Pharma Ltd

+0.02 (+0.13%)
Earnings Announcements

Urogen Pharma Reports Preliminary Jelmyto Sales For Q2

Published: 07/14/2021 13:52 GMT
UroGen Pharma Ltd (URGN) - Urogen Pharma Reports Strong Preliminary Jelmyto® Sales for Second Quarter 2021.
Urogen Pharma Ltd - 73% Growth in Net Product Revenue Over 1q 2021 to Approximately $13.0 Million in 2q 2021.
Urogen Pharma Ltd - 2q 2021 Operating Expenses Anticipated in Range of $33 to $38 Million.
Revenue is expected to be $10.46 Million
Adjusted EPS is expected to be -$1.25

Next Quarter Revenue Guidance is expected to be $14.48 Million
Next Quarter EPS Guidance is expected to be -$1.18

More details on our Analysts Page.